The cluster of differentiation 36 (CD36) is a membrane protein related to lipid metabolism. We show that HCV infection in vitro increased CD36 expression in either surface or soluble form. HCV attachment was facilitated through a direct interaction between CD36 and HCV E1 protein, causing enhanced entry and replication. The HCV co-receptor effect of CD36 was independent of that of SR-BI. CD36 monoclonal antibodies neutralized the effect of CD36 and reduced HCV replication. CD36 inhibitor sulfo-N-succinimidyl oleate (SSO), which directly bound CD36 but not SR-BI, significantly interrupted HCV entry, and therefore inhibited HCV replication. SSO's antiviral effect was seen only in HCV but not in other viruses. SSO in combination with known anti-HCV drugs showed additional inhibition against HCV. SSO was considerably safe in mice. Conclusively, CD36 interacts with HCV E1 and might be a coreceptor specific for HCV entry; thus, CD36 could be a potential drug target against HCV.
Hepatitis C virus (HCV) is a hepatotropic positive-sense single-stranded RNA virus which belongs to Flaviviridae family and is one of the major causes for chronic hepatitis and liver disease worldwide 1 . Since the identification of HCV in 1989, the life cycle and replication mechanism of the virus have been illustrated, and a number of cell surface factors that help HCV entry have been identified 2 . Accumulated data suggest that HCV entry is a complex and multistep process. Non-specific host receptors glycosaminoglycans (GAGs) 3 and the low-density lipoprotein receptor (LDL-R) may facilitate initial attachment of HCV particles on the cell surface 4 . HCV particle appears to interact with a series of cell membrane proteins, including tetraspanin CD81 5 , scavenger receptor class B member I (SR-BI) 6 , tight-junction proteins claudin-1 7 and occludin 8 , followed by clathrin-mediated endocytosis and fusion between the virion envelope and endosomal membrane 9, 10 . Building on the knowledge of these co-factors, Dorner M et al. established a humanized mouse model for HCV infection 11 . However, Hikosaka K et al. showed that expression of human factors CD81, claudin-1, scavenger receptor and occludin in mouse hepatocytes could not confer susceptibility to HCV entry 12 . Another group showed that Tupaia CD81, SR-BI, claudin-1 and occludin supported HCV infection 13 . Recently, Dorner M et al. completed their demonstration on the entire HCV life cycle in genetically humanized mice 14 . These data suggest the existence of unknown cellular factors that help HCV to enter host cells. New host factors co-facilitating HCV particles entry were discovered in the past few years, such as tyrosine kinases epidermal growth factor receptor 15 , ephrin receptor A2 15 , the cholesterol uptake receptor Niemann-Pick C1 like 1 16 , transferrin receptor 1 17 and SR-BI partner PDZK1 18 . The findings provide new information to clarify the detailed mechanism for HCV entry.
Our group has a long history of doing research on compounds that regulate lipid metabolism, in which we found recently that antagonists for cluster of differentiation 36 (CD36) significantly reduced HCV replication in human hepatocytes. The finding caused our interest in the function of this molecule in HCV infection. CD36 is a transmembrane protein and its function is mainly associated with lipid metabolism 19 , but its role in HCV infection is unknown. By using CD36 inhibitors as chemical probes we found that CD36 appears to be another co-factor assisting HCV for attachment on and entry into host cells; blocking the effect of CD36 significantly inhibited HCV replication.
HCV replication was enhanced by CD36.
To learn the role of CD36 in HCV infection, we first examined whether CD36 could affect HCV replication in vitro. Huh7.5 cells were transfected with CD36-HA plasmid. 48 hrs after transfection, the cells were washed and then infected with HCV for 2 hrs, following by washing with PBS and culturing with fresh medium. Intracellular HCV RNA and proteins was detected in 96 hrs. As shown in Fig. 2A , with the increase of CD36 ( Fig. 2A , right, P < 0.01), intracellular HCV RNA ( Fig. 2A , left, P < 0.05) and proteins ( Fig. 2A , right, P < 0.05 for Core, and P < 0.01 for NS3) were significantly higher in the Huh7.5 cells transfected with plasmid CD36-HA as compared with in those transfected with plasmid control. Transfection of CD36 without HA-tag exhibited similar results (not shown), indicating that fusing HA tag at the CD36 C-terminus had no effect on its function. The results suggest an enhancing effect of CD36 in HCV replication. To validate the results, specific siRNA for CD36 was used to silence the endogenous CD36 gene expression in Huh7.5 cells. After 48 hrs transfection of siRNA for CD36, the cells were washed and then infected with HCV, followed by measurement for HCV replication. As shown in Fig. 2B , the intracellular HCV RNA load largely reduced in 96 hrs (Fig. 2B , left, P < 0.01) and HCV proteins (HCV Core and NS3) declined as well (Fig. 2B , right, P < 0.01 for Core and NS3), the positive control siRNA for SR-BI inhibited HCV replication, which is consistent with previous report 26 . Next, we focused on the question of if sCD36 affects HCV replication. The culture supernatants of Huh7.5 cells treated 48 hrs with transfection of CD36-HA plasmid or CD36 siRNA were collected. Naïve Huh7.5 cells were cultured with the above culture supernatants and infected with HCV for 2 hrs; then, supernatants were replaced with fresh media. Intracellular HCV RNA and proteins were detected in 72 hrs. Results showed that the supernatants of Huh7.5 cells transfected with CD36-HA high-expression plasmid enhanced HCV replication (Fig. 2C , left, P < 0.01 for HCV RNA; right, P < 0.01 for HCV proteins), while the supernatants of those transfected with siRNA for CD36 reduced HCV replication (Fig. 2D , left, P < 0.05 for RNA; right, P < 0.01 for proteins). HCV replication appeared to be positively correlated with the concentration of sCD36 in supernatants (P < 0.01), suggesting a role of sCD36 in supporting HCV replication. It appears that HCV infection causes an increased expression and secretion of CD36, which feedbacks an enhancing effect for HCV replication.
Then, specific monoclonal antibodies (mAbs) against CD36 were used to further validate the role of CD36. The three CD36 mAbs were active against 3 CD36 epitope regions that are null of SR-BI sequence. The tests were done for the attachment and entry steps of HCV life cycle. Huh7.5 cells were treated with mAb for 1 hr and then infected with HCV; after 2 hrs infection, the culture supernatants were replaced with fresh media. Quantification of intracellular HCV RNA was performed in 72 hrs. As shown in Fig. 2E , pre-treatment of the cells with CD36 mAb (ab23680 or ab76521) significantly reduced HCV RNA in HCV-infected Huh7.5 cells in a dose-dependent manner. As a positive control, SR-BI antibody significantly reduced HCV RNA in a dose-dependent manner (Fig. 2E) . However, CD36 mAb (ab17044) did not affect HCV replication even at concentration of 5 μ g/mL (Fig. 2E) , suggesting that the antigenic domain of this mAb on CD36 plays no role in HCV entry. These results confirm that CD36 plays a significant role in helping HCV replication at the stage of viral attachment and entry.
Considering that the SR-BI is one of the known HCV receptors 6 and the homology in protein sequences between SR-BI and CD36 is about 30% 27 , we then further examined the joint effect of the mAbs. As shown in Fig. 2F , combination of CD36 mAb (ab23680) with SR-BI specific antibody demonstrated an additional inhibition on HCV replication at the entry stage (P < 0.01, vs IgG; P < 0.05, vs SR-BI or ab23680 alone), suggesting that the domain of CD36 molecule might help HCV entry in a way different from that of SR-BI. However, combination of CD36 mAb (ab76521) with the SR-BI antibody showed no benefit at all in blocking HCV entry, and binding competition might be part of the explanation. In addition, cross-silencing test of the two genes was done to examine the role of CD36. Transfection of specific siRNA for CD36 did not affect the expression of SR-BI (Fig. 2G , right, P > 0.05), whereas silencing SR-BI RNA expression with SR-BI siRNA (sc-44752) inhibited CD36 expression (Fig. 2G , right, P < 0.01 for CD36); and accordingly, the HCV Core or NS3 in SR-BI-silenced cells was lower than that in the CD36-silenced cells (P < 0.05 for Core and NS3) with no cytotoxicity was observed in this experiment (Fig. 2G, left ). It appears that CD36 is a new co-factor for HCV entry, working through coordination with SR-BI.
CD36 facilitated HCV attachment via direct interaction with HCV glycoprotein E1. Next, we examined whether CD36 directly interacts with HCV particle. The culture supernatants of HCV infected Huh7.5 (B) HCV infection increased CD36 expression on Huh7.5 cells and elevated sCD36 in culture supernatants (n = 3; *P < 0.05 and **P < 0.01 vs day 0; # P < 0.05 vs day 2). (C) CD36 expression and sCD36 secretion were increased on Huh7.5 cells infected with HCV for over 60 days (n = 3; *P < 0.05 and **P < 0.01 vs naïve control). Huh7.5 cells were infected with HCV (45IU/cell), proteins and intracellular HCV RNA were respectively detected with WB and qRT-PCR at indicated days after infection in (B,C). The protein bands presented in the figure showed the results of a representative experiment. Data presented are mean ± standard deviation. Student's t-test was used. cells were ultracentrifuged for viral particle collection, followed by protein analysis of the pellets. As shown in Fig. 3A , HCV viral Core and sCD36 were simultaneously detected with western blot in the precipitates. In addition, we used anti-CD36 mAb to pull down HCV particles in the infectious culture supernatants with Co-IP technology; and indeed, sCD36 and HCV particles (Core) were concurrently detected in the immunoprecipitates (Fig. 3B) . To learn what is the HCV proteins that directly interact with CD36, we used anti-CD36 mAb to pull down intracellular HCV components. Western blot results showed that HCV E1, but not E2 or Core, was pulled down by anti-CD36 mAb (Fig. 3C) . The results were consistent with a previous report showing that HCV E2 did not bind CD36 6 . To study whether or not the membrane CD36 could gather HCV particles to facilitate HCV entry, the 293T/17 cells, which are derived from kidney epithelial cells and resistant to HCV infection, were employed. The 293T/17 cells were transfected with CD36 expression vector or siRNA. After 48 hrs incubation, culture supernatants were replaced with fresh media and HCV viral stock was added for a 3 hrs incubation at 37 °C, followed by western blot analysis for HCV proteins in the whole cell lysates. Results (Fig. 3D) showed that HCV particles adhering onto the cell surface were increased in the cells transfected with CD36 expression plasmid (P < 0.05), while cells transfected with CD36 siRNA showed a decreased surface adherence of HCV particles (P < 0.01 for Core, P < 0.05 for E1), and the change was consistent with that of level of CD36. The results suggest that CD36 might directly bind glycoprotein E1 and thus increase the level of HCV particle on cell surface. It might facilitate HCV entry in the early stage of replication.
CD36 inhibitors blocked HCV replication in vitro.
There were several groups of compounds showing selective inhibitory effect on CD36 [28] [29] [30] . If CD36 is really a co-receptor for HCV attachment and entry, those inhibitors should be potential drug candidates against HCV. We therefore selected three types of compounds independently discovered in different laboratories, sulfo-N-succinimidyl oleate (SSO) 28 ( Fig Fig. 4A , right; 4B, right; and 4C right). The different activities against HCV replication among these compounds might be due to their binding on different domains or site of CD36 [28] [29] [30] . These results indicate that CD36 might be a drug target against HCV. To confirm whether SSO inhibited HCV replication via CD36, Huh7.5 cells were transfected with siRNA for CD36 or with CD36 plasmid. After 48 hrs, the cells were infected with HCV and simultaneously treated with SSO for 2 hrs, followed by washing and continuously incubating with fresh media. Intracellular HCV RNA was detected in 96 hrs. Results showed that anti-HCV activity of SSO was increased by transfection with siRNA for CD36 (Fig. 4D , left, P < 0.01), while decreased by transfection with CD36 plasmid (Fig. 4D , right, P < 0.01), suggesting that the level of CD36 will impact the anti-HCV activity of SSO.
As SSO appears to block HCV replication through inhibiting CD36-related viral entry, an anti-HCV mechanism different from that of direct-acting antiviral agents (DAAs) and interferon-alpha (IFN-α ), we combined SSO with DAAs or IFN-α to treat HCV infection. Indeed, addition of SSO enhanced anti-HCV efficacy of telaprevir (VX-950, a protease inhibitor) ( Fig. 4E ; P < 0.05, vs telaprevir alone) and IFN-α ( Fig. 4F ; P < 0.05, vs IFN-α alone), respectively, in HCV-infected Huh7.5 cells, indicating that combination of CD36 inhibitors with known drugs might increase the anti-HCV efficacy.
Antiviral activity of the CD36 inhibitors was also tested for their activity against hepatitis B virus, influenza virus, herpes simplex virus and Coxsackie virus in HepG2.2.15, MDCK and Vero cell cultures, respectively. The SSO showed no inhibitory activity on these viruses. Similarly, W-9 was without effect (Table 1 ). This result suggests that CD36 is a co-factor specific for HCV entry. n = 4 for protein). (D) Low sCD36 in supernatants decreased HCV infection (n = 3 for RNA and cytotoxicity, n = 4 for protein). Huh7.5 cells were incubated with culture supernatants of Huh7.5 cells transfected with 0.2 μ g CD36-HA plasmid (C) or with 150 pmol siRNA for CD36 (D) for 48 hrs, and infected with HCV (150 IU/cell) for 2 hrs, followed by washing and continuously culturing. Intracellular HCV RNA and proteins were detected in 72 hrs, and cytotoxicity was measured with a MTT assay accordingly in D. The pcDAN3.1(+ ) vector was used as plasmid control in A and C. The SR-BI siRNA (sc-44753) was used as positive control and siRNA-A as negative control in (B). *P < 0.05 and **P < 0.01, vs control; # P < 0.05, vs CD36 siRNA. (E) CD36 mAbs neutralized HCV infection in a dose-dependent manner (concentrations of ab17044 were 0.2, 1, and 5 μ g/mL) (n = 3). (F) CD36 mAbs synergistically inhibited HCV infection with SR-BI antibody (n = 4). Huh7.5 cells were incubated with 5 μ g/mL mAb for 1 hr and then infected with HCV (150 IU/cell) for 2 hrs, followed by washing and culturing. Intracellular HCV RNA was detected in 72 hrs (E,F). *P < 0.05 and **P < 0.01, vs IgG group; #, P < 0.05, vs monotherapy with ab23680 or SR-BI antibody. The mAbs code was from Abcam, Co. Ltd. (G) Cross-silencing test of CD36 and SR-BI (sc-44752), and cytotoxicity was measured with a MTT assay (n = 3 for RNA and cytotoxicity, n = 6 for protein). The protein bands presented in the figure showed the results of a representative experiment. Presented are mean ± standard deviation. Student's t-test was used in (A-G).
Scientific RepoRts | 6:21808 | DOI: 10.1038/srep21808 SSO directly bound CD36 and prevented HCV from attachment on host cells. We next investigated the mechanism of SSO in its action against HCV entry. First, the compound SSO was added into cell cultures at the time of before, during and after HCV infection, respectively. Two hrs after viral infection the supernatants were removed and fresh media were added. HCV RNA and proteins were detected in 72 hrs. While SSO treatment before and during HCV infection could strongly inhibit HCV replication in Huh7.5 cells ( Fig. 5A ; P < 0.01), SSO treatment after infection showed no inhibitory effect on HCV ( Fig. 5A ; P > 0.05). It suggested that targeting CD36 by SSO might interrupt HCV replication at the attachment and entry stage.
To further validate the molecular mechanisms of SSO, GS4.3 cells, a human hepatoma Huh-7 cell line carrying an HCV subgenomic replicon I 377-3′ del.S 31 , was used. Indeed, SSO did not inhibit the replication of the sub-gene HCV replicon in GS4.3 cells (Fig. 5B) , as the replicon system did not have E1 protein, and viral attachment/entry steps were absent. The reference drug VX-950 showed strong inhibitory effect on replication of the HCV replicon in GS4.3 cells.
In addition, we investigated whether SSO inactivate HCV particle directly. HCV virus stock was pre-treated with SSO (10 μ M) or VX-950 (0.5 μ M) for 1 hr at room temperature, followed by purification through ultracentrifugation. The pellet was resuspended in fresh culture media to infect Huh7.5 cells (Group 2). SSO-or VX-950-treated HCV with no ultracentrifugation served as controls (Group 1). Intracellular HCV RNA and Fig. 5C , Group 1, P < 0.01), SSO-treated viruses displayed infectivity equal to that of untreated control and negative reference VX-950 in Group 2 (Fig. 5C, Group 2, P > 0.05) . The results indicated a good separation of SSO (and VX-950) from HCV particles in supernatants using ultracentrifugation, and null of direct interaction between SSO and HCV particles.
Then, we determined the kinetics of inhibition on HCV by SSO at the early step of viral life cycle, and a time-of-addition experiment was conducted. HCV remained to be sensitive to bafilomycin A1 (Fig. 5D) , a fusion inhibitor that prevents endosome acidification, for 3 hrs after shifted to 37 °C, consistent with previous reports 32 . In contrast, SSO almost completely lost its activity when added after the temperature shift (Fig. 5D) , indicating that it might act upon a very early step in viral infection.
We then analyzed whether there is a direct interaction between SSO and CD36. Purified CD36-HA protein was fixed onto chips and reacted with SSO in a mobile phase using a BIAcore T100 system. As shown in Fig. 5E , a direct binding between CD36 and SSO was detected, and the interaction was in a dose-dependent manner (Fig. 5E, insert) , suggesting that the anti-attachment activity of SSO on HCV entry might be mediated via a direct binding of the compound onto CD36. And, the molecule interaction was in a covalent fashion (Fig. 5E, insert) , which were consistent with the previous report 28 . As negative control, VX-950 did not bind onto CD36 (Fig. 5F , left). Also, SSO (or VX-950) showed no binding on SR-BI (Fig. 5F , middle and right), indicating a selectivity of SSO on CD36.
For detecting whether SSO will impact the interaction between CD36 and HCV E1, Co-IP assay was carried out. Result showed that SSO could directly disrupt the interaction between CD36 and HCV E1 (Fig. 5G) , suggesting that the binding of SSO to CD36 will disrupt the direct interaction between CD36 and HCV E1.
CD36 inhibitors were safe in vivo. Normal KM mice were orally treated with a single dose of SSO in a range between 250 to 1000 mg/kg, and the mice were followed up for 7 days. As shown in Fig. 6 , none of the mice died in the groups treated with SSO, and body weight change was not observed (Fig. 6A ). Blood samples were taken at the end of the experiment and liver as well as kidney functions were examined. Even at a dose up to 1000 mg/kg, abnormality was not detected in blood GOT, GPT, BUN and CRE (Fig. 6B) , suggesting that CD36 inhibitor SSO was relatively safe in vivo. Considering that SSO strongly inhibited HCV replication and was with high SI in hepatocytes, CD36 might a potential target to develop new mechanism anti-HCV agents.
Discussion
CD36, also known as fatty acid translocase (FAT), is an integral membrane glycoprotein and belongs to the class B scavenger receptor family which includes receptors for selective cholesteryl ester uptake, scavenger receptor class B type I (SR-BI) and lysosomal integral membrane protein II (LIMP-II) 33 . CD36 combines with a variety of ligands and plays an important role in various physiological and pathological processes, such as the formation of macrophage foam cells, atherosclerosis, angiogenesis, diabetes mellitus, thrombosis, malaria, Alzheimer's disease, obesity, and tumorigenesis as well, and thus may be a potential target to drug discovery 20, 34 . Soluble CD36 (sCD36), a cell-free form of CD36 35 , is significantly associated with indices of insulin resistance, carotid atherosclerosis and fatty liver 36 . Clinical study showed an increased expression of CD36 on liver cells and elevated blood level of sCD36 in subjects infected with HCV [23] [24] [25] , however, the biological significance remains unclear. We showed in this study that HCV infection increased expression of CD36 in hepatocytes and elevated secretion of sCD36 in cell culture supernatants, confirming the clinical observation mentioned above. However, Himoto T et al. showed that the loads of HCV RNA did not affect the serum sCD36 levels in patients with HCV-related chronic liver disease, and they conjectured that sCD36 levels are regulated by host factors rather than the viral factors themselves 24 . It is reported that HCV core protein increases hepatic lipid accumulation via elevating transcriptional activity of peroxisome proliferators-activated receptor gamma (PPAR-gamma) 37 , which is important in regulation of a number of genes involved in hepatic fatty acid synthesis, and its transcriptional activation up-regulates expression of CD36 [38] [39] [40] . So the level of CD36 (or sCD36) was up-regulated by HCV infection might be through the increase of PPAR-gamma transcriptional activity caused by HCV Core. The detailed mechanism needs to be further clarified.
The membrane CD36 contributed to the HCV replication through facilitating the viral attachment on host cell membrane. Molecular mechanism study showed that HCV E1 protein on the surface of viral particles could directly bind membrane CD36, helping HCV to complete its entry process. The sCD36 increased HCV entry as well, but the mechanism is not understood. There could be at least two explanations: first, binding of sCD36 with its ligand (HCV E1) might induce formation of CD36 dimers or multimers with those on membrane 41 ; or/and second, sCD36 in a complex with HCV E1 might increase adherence on cell surface through interacting with cell) and simultaneously treated with 5 μ M SSO for 2 hrs, followed by washing and continuously incubating with fresh media. Intracellular HCV RNA was detected in 96 hrs. *P < 0.05 and **P < 0.01, vs siRNA (or plasmid) control plus solvent control group; ## P < 0.01, vs siRNA (or plasmid) control plus SSO group. (E) SSO in combination with VX-950 inhibited HCV replication in an additive manner (n = 3 for RNA, n = 4 for protein). (F) Increased anti-HCV effect of SSO in combination with IFN-α (n = 3 for RNA, n = 4 for protein). Huh7.5 cells were infected with HCV (45 IU/cell) and incubated with SSO (1.0 μ M) or VX-950 (0.1 μ M), or the combination of SSO and VX-950 (E), or incubated with IFN-α (1.0 U/mL), or the combination of SSO and IFN-α (F). Intracellular RNA and proteins were detected in 72 hrs. *P < 0.05 and **P < 0.01, vs solvent control; # P < 0.05, vs VX-950 or IFN-α alone. The protein bands showed the results of a representative experiment. Presented are mean ± standard deviation.
Student's t-test was used in (D-F).
Scientific RepoRts | 6:21808 | DOI: 10.1038/srep21808 membrane proteins 42 . Our results showed that HCV infection causes an increased expression and secretion of CD36, and in turn, the elevation of CD36 (or sCD36) would facilitate HCV replication. Normally, virus infection could prevent superinfection. HCV infection of Huh 7 cells down-regulated the expression of CLDN1 and occludin, and thus prevented superinfection 43 . However, HCV superinfection exclusion was neither due to a reduction of cell surface expression of CD81 and scavenger receptor BI, two molecules implicated in HCV entry, nor due to a functional block at the level of virus entry 44 . The mechanism and consequence is still to be clarified, especially in vivo. sCD36 is a cell-free form of CD36 showing positive correlation with membrane CD36 expression and HCV replication, thus it might be a biomarker in HCV infected individuals.
CD36 has a protein sequence with 30% homology to that of SR-BI 27 , a known host factor for HCV entry 6 . Thus, three CD36-specific mAbs were used in these study, and we found that two out of three were active against HCV entry; combination of CD36 mAb with SR-BI antibody showed additional inhibition on HCV replication. The results suggested that CD36 contributes to HCV entry via a mode of action independent of that by SR-BI. Indeed, CD36 and SR-BI binds different proteins of HCV. A previous report showed that SR-BI selectively bound HCV E2, but CD36 did not 6 ; and we show here that CD36, but not SR-BI, bound HCV E1. As HCV entry requires presence of both E1 and E2 proteins on viral surface 45, 46 , it explains the additional anti-HCV effect when the CD36 mAb was used in combination with SR-BI antibody.
CD36 is expressed on several types of mammalian cells and has multiple effects in biology 20 , especially in lipid metabolism. Thus, one of the concerns was that whether inhibition of CD36 will hurt physiological functions in vivo. Independent studies of several groups have shown that deficiency or null of CD36 was not lethal, and caused only metabolic disorders in rat or in human 47, 48 , suggesting a promise in safety. Thus, it is suggested that CD36 may be a potential drug target for lipid metabolism [28] [29] [30] 49 . For many years, interferon (IFN-alpha) in combination with ribavirin has represented a standard therapy of HCV infection, although the efficacy is not satisfactory 50 . Recently, several DAAs were approved for clinic use 51 , including NS3/4A serine protease inhibitors telaprevir, boceprevir and simeprevir, as well as NS5B polymerase inhibitor sofosbuvir. These drugs have improved the overall therapeutic efficacy on hepatitis C. However, as the agents target specific HCV enzymes, emergence of drug-resistant viral strains could be a hurdle in near future 52, 53 . To address the concern, research efforts have been mainly focused on combination therapy as well as new mechanism drugs inhibiting viruses through host factors 54, 55 . Drugs that inhibit virus via regulating host environment might have less chance of inducing drug-resistant mutation 56 .
In conclusion, our results showed that membrane protein CD36 expressed in liver cells appears to be a co-receptor for binding with HCV E1 protein in the attachment stage. Blocking CD36 with its inhibitors significantly interrupts HCV replication. We consider CD36 a potential drug target against HCV.
Materials and Methods
Cells and HCV. Huh7.5 cells and the plasmid pFL-J6/JFH/JC1 containing the full-length chimeric HCV complementary DNA (cDNA) were kindly provided by Vertex Pharmaceuticals, Inc. HCV virus stock was prepared as previously described 57 . 293T/17 cells (from ATCC) and GS4.3 replicon cells were cultured as described previously 58, 59 .
Agents. Sulfo-N-succinimidyl oleate (SSO, sc-208408), bafilomycin A1 (sc-201550) and siRNAs for CD36 (sc-29995), SR-BI (sc-44752 and sc-44753) and negative control (siRNA-A, sc-37007) were from Santa Cruz Biotechnology, Inc. The compounds W-9 and AP5055 were synthesized in the Medicinal Chemistry Laboratory of Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, in a purity greater than 98.5%. The structures of the compounds were confirmed with proton nuclear magnetic resonance spectroscopy and mass spectrometry spectra. Telaprevir/VX-950 (HY-10235) was from MedChemExpress, Inc. The antibody to SR-BI (NB400-104) was from Novus Biological, Inc. The mAbs to human CD36 (ab17044, ab23680, ab76521 and ab133625), HCV core (ab2740), HCV NS3 (ab13830), control IgG 1 (ab18447) and Nrf2 antibody (ab31163) were from Abcam, Co. Ltd. The mAb to beta-Actin (TA-09) was from Beijing ZSJQ-BIO, Co. Ltd. The antibodies to HCV E1 (GTX103352) and E2 (GTX103353) were from Gene Tex, Inc. The mAb to HA tag (6E2) (2367S) and the secondary antibodies (7074S and 7076S) were from Cell Signaling Technology, Inc.
Plasmids. The plasmids pcDNA3.1(+ )-CD36 expressing CD36, pcDNA3.1(+ )-CD36-HA expressing CD36
with HA tag at the C-terminal, and pZeoSV2(+ )-SR-BI-HA expressing SR-BI with HA tag at C-terminal were cloned from Huh7.5 cell with primers shown in Table 2 . The sequences were confirmed by sequencing and assay of restriction endonucleases respectively. Over expression and silence. Huh7.5 cells were transfected with 0.2 μ g CD36-HA plasmid or plasmid control pcDNA3.1(+ ) using HD transfection reagent (Promega), or transfected with 150 pmol siRNA for CD36 or SR-BI or negative control siRNA-A using RNAiMAX transfection reagent (Invitrogen). After 48 hrs, the culture supernatants were harvested to extract proteins or to treat naïve Huh7.5 cells. The transfected cells were washed and then infected with HCV (150 IU/cell) for 2 hrs, followed by washing and culturing with fresh medium. After 24 hrs, the cells were subcultured, or intracellular proteins were extracted to detect CD36 expression with WB. Naïve Huh7.5 cells were cultured with 2 ml of above culture supernatants and simultaneously infected with HCV (150 IU/cell) for 2 hrs, followed by washing and culturing with fresh medium. 72 hrs later, the intracellular HCV RNA was extracted with RNeasy Mini Kit (Qiagen) and total intracellular proteins were extracted with PER 2 −△△CT method, and all quantifications were normalized to the level of the internal control gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 60 , The sequences of primer pairs and probes for HCV RNA and GAPDH were shown in Table 2 .
Western blot. The western blot was performed as previously described 57 . After SDS-PAGE and trans-Membrane, the target proteins were accordingly probed with anti-HCV Core antibody (1:2500), or anti-HCV NS3 antibody (1:2500), or anti-CD36 antibody (ab133625, 1:2500) or anti-SR-BI antibody (1:2500), or anti-HA tag antibody (1:1000), respectively. As a control, anti-Actin antibody (1:4000) was used. The proteins were detected using Immobilon Western Chemiluminescent HRP Substrate (Millipore, Inc.) with Alpha Innotech Focus and Image Acquisition (Alpha Innotech, Inc.). The protein signal intensity was scanned with Gelpro32 software, the ratio of interested protein to internal control protein Actin was calculated, and normalized as 1.00 for the control group.
BIAcore. The 293T/17 cells were transfected with CD36-HA or SR-BI-HA plasmid using HD transfection reagent. At 48 hrs post transfection, cells were harvested and protein CD36-HA or SR-BI-HA was purified with Pierce Anti-HA Agarose (Thermo Scientific) and then desalinated with Zeba Spin Desaling Columns (Thermo Scientific). The concentration of purified proteins was quantified with Pierce BCA Protein Assay Kit (Thermo Scientific). Then, surface plasmon resonance experiments were performed on a BIAcore biosensor system (BIAcore T100). In brief, the carboxymethylated surface of series S sensor chip CM5 (GE Healthcare Bio-Sciences) was first activated with a mixture of N-hydroxysuccinimide (NHS) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydro-chloride (EDC) (BIAcore AB). Subsequently, 200 μ L of purified CD36-HA or SR-BI-HA at a concentration of 80 μ g/mL was injected into the flow cell (FC2) for immobilization on the sensor surface. To analyze the binding of SSO with CD36 or SR-BI protein, 160 μ L of SSO [50, 100, 200 , 500 μ M in HBS-EP + buffer (GE Healthcare Bio-Sciences)] were injected and followed by flowing the buffer. Compound VX-950 was used as negative control. Data were evaluated using the software BIAcore T100 Evaluation (BIAcore AB).
Interaction between HCV and compounds. HCV viral stock was treated with SSO (10 μ M) or VX-950 (0.5 μ M) or solvent control for 1 hr at room temperature. Group 1 was not centrifuged and used as control; Group 2 was ultracentrifuged at 30000 × g for 4 hrs at 4 °C, and the pellet was resuspended with complete culture medium. Huh7.5 cells were infected with above treated-HCV (45 IU/cell), and intracellular HCV RNA and proteins were detected in 72 hrs.
Time-of-addition assay. Huh7.5 cells were infected with HCV (300 IU/cell) and incubated at 4 °C for 2 hrs, the cells were then washed with cold PBS and shifted to 37 °C (set as 0 hr time point) to initiate synchronous infection. At − 2, − 1, 0, 1, 2, 3, 4 hr, 10 μ M SSO, or 10 nM bafilomycin A1, or solvent control was added, and the cells were incubated for 2 hrs prior to removal (the exception is t = − 2 hr and − 1 hr where compound were added back after removal of the virus and incubated for additional 2 hrs prior to removal). Intracellular HCV RNA was detected after 72 hrs incubation. Inhibitory ratio was calculated as % relative to infectious control (0%). Fitted lines represent sigmoidal time-dependent curves 32 .
Interaction between HCV and sCD36. Culture supernatants were collected from HCV infected Huh7.5 cells and centrifuged at 1000 × g for 10 minutes at 4 °C, and then ultracentrifuged at 30000 × g for 1 hr at 4 °C. Equal amounts of culture media from naïve Huh7.5 cells were used as negative control. The proteins in precipitates were detected with WB.
293T/17 cell line model. 293T/17 cells were transfected with 1 μ g CD36 plasmid or plasmid control pcDNA3.1(+ ) using HD transfection reagent, or transfected with 150 pmol siRNA for CD36 or control siRNA-A using RNAiMAX transfection reagent. 48 hrs later, the cells were washed with PBS and then infected with HCV (300 IU/cell) for 3 hrs at 37 °C. After washing 3 times with PBS, the cells were lysed with PER and proteins were detected with WB. Statistical analysis. Data shown in the histogram were mean ± standard deviation of over 3 independent experiments. Data were analyzed using ANOVA analysis and Student's t-test. The level of significance was set at P < 0.05.
Safety of SSO

